Safety and Efficacy of Antimicrobial Peptides against Naturally Acquired Leishmaniasis-Reference-Cited by-同舟云学术

Safety and Efficacy of Antimicrobial Peptides against Naturally Acquired Leishmaniasis

Published:2004-02 Issue:2 Volume:48 Page:641-643
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Alberola J.¹,Rodríguez A.¹,Francino O.²,Roura X.³,Rivas L.⁴,Andreu D.⁵

Affiliation:

1. Departament de Farmacologia, Terapèutica i Toxicologia

2. Departament de Ciència Animal i dels Aliments

3. Hospital Clínic Veterinari, Facultat de Veterinària, Universitat Autònoma de Barcelona, 08193 Bellaterra, Barcelona

4. Centro de Investigaciones Biológicas, Velázquez 144, 28006 Madrid

5. Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, 08003 Barcelona, Spain

Abstract

ABSTRACT Leishmaniases, which are important causes of morbidity and mortality in humans and dogs, are extremely difficult to treat. Antimicrobial peptides are rarely used as alternative treatments for naturally acquired parasitic diseases. Here we report that the acylated synthetic antimicrobial peptide Oct-CA(1-7)M(2-9) is safe and effective for treating naturally acquired canine leishmaniasis.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.48.2.641-643.2004

Reference37 articles.

1. Akuffo, H., D. Hultmark, A. Engstom, D. Frohlich, and D. Kimbrell. 1998. Drosophila antibacterial protein, cecropin A, differentially affects non-bacterial organisms such as Leishmania in a manner different from other amphipathic peptides. Int. J. Mol. Med.1:77-82.

2. Mapping and Sequencing of the Canine NRAMP1 Gene and Identification of Mutations in Leishmaniasis-Susceptible Dogs

3. Andreu, D., and L. Rivas. 1998. Animal antimicrobial peptides: an overview. Biopolymers47:415-433.

4. Baneth, G., and S. E. Shaw. 2002. Chemotherapy of canine leishmaniosis. Vet. Parasitol.106:315-324.

5. Bauer, R. J., M. L. White, N. Wedel, B. J. Nelson, N. Friedmann, A. Cohen, W. N. Hustinx, and A. H. Kung. 1996. A phase I safety and pharmacokinetic study of a recombinant amino terminal fragment of bactericidal/permeability-increasing protein in healthy male volunteers. Shock5:91-96.

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling the role of antimicrobial peptides in plant resistance against phytopathogens;Discover Sustainability;2024-09-05

2. Compounds with potentialities as novel chemotherapeutic agents in leishmaniasis at preclinical level;Experimental Parasitology;2024-05

3. Current and emerging therapies for the treatment of leishmaniasis;Expert Opinion on Orphan Drugs;2024-04

4. Therapeutic evaluation of activatable melittin for selective treatment of leishmaniasis in vitro and in vivo;BULGARIAN JOURNAL OF VETERINARY MEDICINE;2024

5. Neglected Zoonotic Diseases: Advances in the Development of Cell-Penetrating and Antimicrobial Peptides against Leishmaniosis and Chagas Disease;Pathogens;2023-07-15